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Abstract: Background: The most serious and potentially life threatening iatrogenic complication of controlled 
ovarian hyperstimulation (COH) is a severe form of ovarian hyperstimulation syndrome (OHSS). It complicates less 
than 0.5-2% of In Vitro Fertilization (IVF) cycles which cause mortality in 1/45000 – 1/50000 per infertile women 
receiving gonadotrophins. The diagnosis and severity of OHSS were determined using standard criteria. OHSS has 
been treated empirically over the years, because it is Pathophysiology remained unknown. Vascular endothelial 
growth factor (VEGF) is a powerful mediator of vascular permeability; it is also strongly implicated in the initiation 
and development of angiogenesis in the developing embryo and in adult tissue undergoing profound angiogenesis, 
such as cycling endometrium and the luteinizing follicle. It also plays an important role in the growth and 
maintenance of ovarian follicles and corpus luteum by mediating angiogenesis. Objectives: To compare the effects 
of cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent ICSI. 
Study design: Prospective randomized trial. Patients and Methods: The study included an intervention and a control 
group. Cabergoline group: 30 patient's received 0.25mg cabergoline tablet per day starting on day of hCG injection 
and continued for 8 days. Control group: cabergoline tablet was not given after hCG injection in 30 patients. Results: 
There was no significant difference between baseline characteristics or ovarian stimulation parameters from the two 
groups. The incidence of OHSS in the cabergoline-treated group, was significantly (P=0.01) lower than that in the 
control group (12% vs. 36%). Higher rates of clinical and chemical pregnancy were observed after cabergoline 
administration in ICSI cycles. Conclusions: The present study showed that cabergoline reduces the incidence of 
OHSS in ICSI cycles. Women at high risk of OHSS, cabergoline can be administered as soon as the hCG injection 
to prevent early OHSS. Higher rates of clinical and chemical pregnancy were observed after cabergoline 
administration in ICSI cycles. 
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1- Introduction 
Ovarian hyperstimulation syndrome (OHSS) 
is a potentially life-threatening situation, and thus 
regarded to be the most serious complication of 
assisted reproduction treatment (ART). It is 
characterized by the presence within the ovaries of 
multiple luteinized cysts, which leads to ovarian 
enlargement and secondary complications such as 
increased capillary permeability and fluid shift to 
the third space.1 
Findings at 2008 have identified vascular 
endothelial growth factor (VEGF) as the major 
molecule responsible for increased capillary 
permeability.1 The production of VEGF in ovarian 
follicles increases during stimulation period, and 
results in a rapid increase in vascular permeability 
upon binding to type 2 VEGF receptors.1 Although, 
cytokines and growth factors (interleukins IL-2, IL-
6, IL-8, IL-10, and IL-18), histamine, prolactin, 
prostaglandins and renin-angiotensin have been 
proposed as participants in OHSS pathophysiology, the 
exact responsible factor is under debate.2 
Standard treatments for OHSS are generally 
conservative, and potentially life-threatening 
complications of OHSS, which require costly long-term 
hospitalizations, render prophylactic measures a must.3,4 
Some approaches, which are based on the 
pathophysiology of OHSS, are now applied for its 
prevention. Studies show a reduced incidence of OHSS 
when recombinant luteinizing hormone (rLH) or a 
gonadotropin releasing hormone (GnRH) analogue is 
used to trigger the final steps of oocyte maturation. 
Prophylactic administration of cabergoline, a dopamine 
agonist, is associated with a significant reduction in the 
incidence of symptoms and signs of moderate to severe 
OHSS. This drug inhibits vascular endothelial growth 
factor 2 (VEGFR-2) phosphorylation and signaling. Its 
use is not associated with an inferior ART outcome or 
obstetric/neonatal complications.2,4-6 
Bused upon this consideration this study was 
conducted to compare the effects of cabergoline in the 
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prevention of the early onset ovarian 
hyperstimulation syndrome (OHSS) in high-risk 
women underwent ICSI. 
 
2- Material and Methods 
This prospective randomized study was 
performed in the Assisted Reproductive 
Technologies Unit, Benha University Hospital and 
in private IVF centers. The study protocol was 
approved by the Local Ethics Committee and 
written informed consents were obtained before the 
study started. 
High risk patients were defined as young 
females, who had antral follicle counts of more 
than 15, poly cystic ovaries on ultrasound scan 
and/or polycystic ovarian syndrome (PCOS), serum 
estradiol of more than 2500 picogram per milliliter 
(pg/ml) and/or multiple follicular recruitments in 
both ovaries during ultrasound monitoring in 
controlled ovarian hyperstimulation (COH) (More 
than 20 follicles > 12 millimeter (mm) on the 10th 
of the cycle) 2. 
The inclusion criteria were an age of 25- 30 
years, high risk of developing OHSS. Polycystic 
ovarian syndrome was diagnosed according to 
Rotterdam criteria.8 According to the Rotterdam 
criteria, patients with two of the three 
characteristics including: 1) oligomenorrhea/ 
amenorrhea, 2) clinical (hirsutism) finding of 
hyperandrogenism, or 3) polycystic ovaries on 
transvaginal sonography, were included in the 
study. Metabolic features of PCOS patients were 
not of concern in this study; therefore, insulin 
resistance and androgen index were not measured. 
The oligomenorrhea/amenorrhea and polycystic 
appearance of ovaries were seen in more than two 
third of the PCOS patients. 
All patients were on long protocol starting 
gonadotrophin releasing hormone analogue (Gn Rh) 
on midluteal phase of the proceeding menstrual 
cycle. After confirmation of down regulation (basal 
E2 level > 35 pg/ml.), ovulation induction was 
started using human menopausal gonadotrophin 3 
ampoule per day, and the dose was adjusted 
according to response. When 3 or more leading 
follicles reaching 18-20 mms, 10000 IU of hCG 
was given, oocyte retrieval was done 34 hours later. 
Ultrasound guided intrauterine embryo transfer (ET) 
of 3 embryos was done after 48 hours. 
The participants were divided in two groups. 
The first group (cabergoline group) comprised 30 
women treated with 0.25 mg of cabergoline 
(Dostinex®, Pharmacia Italia S.P.A, Italy) every 
day for eight days commencing on the day of hCG 
administration. If OHSS occurred, the standard 
conservative and supportive management for 
OHSS was employed. The second group (control group) 
was comprised of 30women, who were similar to the 
former group with respect to age as well as the number 
and quality of the retrieved oocytes, number and quality 
of the transferred embryos, and the sperm quality. The 
latter group did not receive Cabergoline; however, their 
OHSS (if occurred) were managed conservatively 
according to our standard protocols after hospital 
admission. All OHSS patients were admitted to the 
hospital, and the diagnosis of OHSS as well as its 
severity was performed according to a standard 
definition.9 The standard classification categorizes the 
disease based on its severity to mild, moderate, and 
severe OHSS. In mild OHSS, patients often report mild 
abdominal distention and soreness, nausea, vomiting, and 
ovarian enlargement between 5 to 12 cm. Moderate 
diseases were characterized by the presence of abdominal 
ascites on ultrasound examination. Severe diseases were 
diagnosed when there are clinical signs of tense ascites, 
hydrothorax, shortness of breath, hemoconcentration, 
hypercoagulability, or any complications of OHSS such 
as renal failure, thromboembolism, or acute respiratory 
distress syndrome (ARDS).9 
The investigators filled out a standard questionnaire 
for each participant. Data were collected from the 
questionnaires through complete history taking, general 
examination.local examination, laboratory notes and 
ultrasound reports. Age, number of retrieved oocytes, 
number of follicles on day of hCG administration, 
assessment of mean ovarian diameter (MOD), estradiol 
level on the day of hCG administration were recorded. 
Chemical pregnancy was detected by the measurement of 
serum beta-hCG 14 days after the embryo transfer. The 
existence of clinical pregnancy was confirmed using 
transvaginal ultrasound scan, which was scheduled two 
weeks later to detect the gestational sac of pregnancy. 
Patients were followed until the detection of fetal heart 
pulsation. Early OHSS (mild, moderate and severe). 
Early OHSS was defined as the onset of the syndrome 
during the first 9 days after HCG administration. All of 
the patients were checked for any complaints or side 
effects of cabergoline, however, none of them reported 
any side effects. 
Statistical analysis 
Quantitative data are presented as mean ± SD. 
Quantitative and qualitative data were analyzed using 
Student's t test, and Chi-square or fisher’s exact test, 
respectively. The data were analyzed using Statistical 
Package for Social Sciences (SPSS version 14, (SPSS 
Inc., Chicago, IL). A p value of less than 0.05 was 
considered statistically significant. 
3- Results 
The mean age was 27.47 years for cabergoline 
group and 27.87 years for control group, with no 
significant deference (P value= 0.626). Both groups are 
comparable for age. Also, there was no significant 
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difference between the two groups in terms of 
infertility duration, serum estradiol levels on the 
day of hCG administration, body mass index (BMI) 
and serum levels of FSH and LH (Table 1). 
Moreover, there was no significant difference 
between the number of follicles and mean ovarian 
diameter (Table 1). The incidence of OHSS in 
cabergoline group was 4 (13.3%) total cases, 
[3(10%) mild OHSS and 1(3.3%) moderate OHSS] 
and in control group was 13 (43.33%) total cases, 
[9(30%) mild OHSS and 4(13.3%) moderate 
OHSS]. Statistical evaluation showed significant 
deference between the incidence of OHSS in both groups 
(P value =0.035) (Table 2). The incidences of no, mild 
and moderate and OHSS in cabergoline-treated groups 
were 86.7%, 10% and 3.3%, and in the control group 
were 56.7%, 30 %, 13.3%, respectively (Table 2). There 
was significant deference between the studied groups 
according to chemical pregnancy, positive serum β HCG 
(P value =0.039) ( Table 2). There was significant 
deference between the studied groups according to fetal 
heart pulsation (P value =0.028) (Table 2). 
 
Table 1: Baseline characteristics of patients in cabergoline-treated and control groups 
Baseline characteristics Cabergoline (n=30) Control (n=30) P value 
Age (year) 27.47±2.18 27.87±1.53 0.626 
Duration of infertility(Year) 6.67±2.28 6.27±1.86 0.459 
E2 level(pg/ml) 3610.3± 842.65 3686.6± 834.76 0.726 
Number of follicles 16.3±2.52 17.37±2.13 0.82 
Mean ovarian diameter MOD(cm) 7.43±2.11 8.3±2.07 0.114 
BMI (kg/m2) 24.86±6.83 24.08±3.65 0.596 
FSH (IU/L) 5.88±1.5 5.54±1.6 0.90 
LH (IU/L) 7.28±2.1 5.21±1.9 0.78 
Values are presented as mean± SD or frequency (percent). 
 
Table 2: The outcomes of ovarian stimulation in cabergoline-treated and control groups 
Outcome of ovarian stimulation Cabergoline (n=30) Control ((n=30) P value 
OHSS 4(13.33%) 13 (43.33%) 0.001 
No 26(60.5%) 17(39.5%) 0.08 
Mild 3 (25.0%) 9 (75.0%) 0.023 
Moderate 1 (20.0%) 4 (80.0%) 0.047 
Chemical pregnancy(Positive β HCG) 19(63.3%) 11 (36.7%) 0.039 
Clinical pregnancy(Positive fetal heart pulsation ) 17(89.5%) 5(45.5%) 0.028 




OHSS is an iatrogenic complication of ovarian 
stimulation that occurs during either the luteal phase 
or early pregnancy. The most common form occurs a 
few days after the induction of the follicular rupture 
following the administration of hCG when follicular 
growth has been medically induced. The most serious 
and potentially life threatening iatrogenic 
complication of COH is a severe form of OHSS. 
OHSS has been treated empirically over the years, 
because it is pathophysiology remained unknown, the 
underlying feature of OHSS is increased capillary 
permeability leading to a fluid shift from the 
intravascular space to third space compartments. As 
this is an iatrogenic complication of a non-vital 
treatment with a potential fatal outcome, the syndrome 
remains a serious problem for specialists dealing with 
infertility. 14 
Cabergoline, a dopamine agonist inhibiting 
VEGFR-2 phosphorylation and signalling, effectively 
reduced the incidence of OHSS and cycle cancellation 
without any adverse effects on pregnancy. The 
findings of the present study are in agreement with 
those of previous studies.3,5,6,10. Considering the 
physical and psychological consequences along with 
medical costs like hospitalization, every intervention 
to decrease VEGF expression or antagonizing its 
effects would be valuable. 
The ovary is the main source of cytokines and 
VEGF, which are mediators that cause increased 
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capillary permeability and ascites. It has been 
suggested that parameters of ovarian activity during 
stimulation such as serum levels of estradiol and 
number of oocytes retrieved correlate closely with 
VEGF gene expression.1 Cabergoline decreases the 
phosphorylation of VEGFR2.10 Animal studies have 
demonstrated that the expression of gene for tyrosine 
hydroxylase enzyme, which is the rate-limiting 
enzyme in dopamine synthesis, is significantly lower 
in rats with overstimulated ovaries.11 High VEGF 
expression and activity in OHSS seem to be associated 
with reduced dopamine production. Cabergoline 
significantly reduced VEGFR2-dependent vascular 
permeability in rats with OHSS. Moreover, serum 
levels of progesterone and rates of luteal apoptosis 
remained unchanged, suggesting the absence of a 
luteolytic effect of cabergoline.12 
Alvarez and colleagues,3 conducted a 
randomized, placebo-controlled double-blind clinical 
trial in oocyte donors at risk of OHSS, and found that 
the incidence of moderate or severe OHSS was 
significantly reduced in the cabergoline-treated group, 
without an adverse effect on ovarian function. In a 
retrospective analysis,6 Alvarez and colleagues 
showed that implantation and clinical pregnancy rates 
in women who received cabergoline for the prevention 
of OHSS was similar to those in women matched for 
age, embryo quality, and semen parameters. 
Another study,13 compared early OHSS, defined 
as the onset of the syndrome during the first nine days 
after HCG administration, and late OHSS, 
characterized by the onset of the syndrome after 10 
days after HCG administration. Cabergoline decreased 
the risk of early OHSS significantly. There was 
significant difference between the two groups in terms 
of pregnancy.13 Though not a randomized clinical trial, 
the findings of our study, namely decreasing the 
incidence of early OHSS, are in agreement with those 
of such a report.13 Although the incidence of mild 
OHSS decreased. Moreover, the effects of the 
cabergoline found in the present study are in 
agreement with those of previous publications.3-6,10 
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